HK1100260A1 - Binding peptidomimetics and uses of the same - Google Patents

Binding peptidomimetics and uses of the same

Info

Publication number
HK1100260A1
HK1100260A1 HK07104723.9A HK07104723A HK1100260A1 HK 1100260 A1 HK1100260 A1 HK 1100260A1 HK 07104723 A HK07104723 A HK 07104723A HK 1100260 A1 HK1100260 A1 HK 1100260A1
Authority
HK
Hong Kong
Prior art keywords
monomers
nucleic acid
disclosed
acid molecule
same
Prior art date
Application number
HK07104723.9A
Other languages
English (en)
Inventor
Mark I Greene
Ramachandran Murali
Hongtao Zhang
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of HK1100260A1 publication Critical patent/HK1100260A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK07104723.9A 2004-02-20 2007-05-03 Binding peptidomimetics and uses of the same HK1100260A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54622404P 2004-02-20 2004-02-20
PCT/US2005/005383 WO2005081898A2 (en) 2004-02-20 2005-02-18 Binding peptidomimetics and uses of the same

Publications (1)

Publication Number Publication Date
HK1100260A1 true HK1100260A1 (en) 2007-09-14

Family

ID=34910756

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07104723.9A HK1100260A1 (en) 2004-02-20 2007-05-03 Binding peptidomimetics and uses of the same

Country Status (8)

Country Link
US (1) US7906624B2 (xx)
EP (2) EP2392586A1 (xx)
JP (1) JP2007528725A (xx)
AT (1) ATE536367T1 (xx)
AU (1) AU2005216126B2 (xx)
CA (1) CA2556832A1 (xx)
HK (1) HK1100260A1 (xx)
WO (1) WO2005081898A2 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE483466T1 (de) 2002-05-23 2010-10-15 Univ Pennsylvania Fas peptid-mimetika und ihre verwendungszwecke
WO2008134761A2 (en) * 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
JP2013528174A (ja) 2010-05-28 2013-07-08 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム オリゴベンズアミド化合物およびそれらの使用
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8835493B2 (en) 2011-11-23 2014-09-16 Board Of Regents, The University Of Texas System Oligo-benzamide compounds for use in treating cancers
WO2013078277A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
CN110841074B (zh) 2014-03-21 2023-07-18 艾伯维公司 抗-egfr抗体及抗体药物偶联物
WO2017015064A1 (en) * 2015-07-20 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Detection phenotyping and quantitation of cells with multimeric binding reagent
CA3027033A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CA3027103A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
US20200002421A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
SG10201914119TA (en) 2016-06-08 2020-02-27 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates
CA3064697A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
CN107236046B (zh) * 2017-05-15 2021-05-07 江苏吴中医药集团有限公司苏州中凯生物制药厂 一种重组人内皮抑素融合蛋白及其制备方法和应用
JP7289029B2 (ja) 2017-07-10 2023-06-09 エスアールアイ インターナショナル 分子誘導システムペプチド及びその使用
US11738089B2 (en) 2017-07-10 2023-08-29 Sri International Peptide saporin conjugate for the treatment of cancer
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334702A (en) 1991-03-25 1994-08-02 University Of Illinois Compositions which are immunologically crossreactive with antibodies and preparative methods therefor
US5665539A (en) 1991-07-12 1997-09-09 The Regents Of The University Of California Immuno-polymerase chain reaction system for antigen detection
US5328985A (en) 1991-07-12 1994-07-12 The Regents Of The University Of California Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
US6391590B1 (en) 1991-10-21 2002-05-21 The Regents Of The University Of California Recombinant streptavidin-metallothionein chimeric protein having biological recognition specificity
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
US6100377A (en) 1994-06-10 2000-08-08 The Trustees Of The University Of Pennsylvania Constrained peptides
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6497881B1 (en) 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US5922553A (en) 1996-11-21 1999-07-13 Trustees Of The University Of Pennsylvania Method of detecting protein by immuno RNA
EP1042459A4 (en) * 1997-12-24 2003-07-23 Diatech Pty Ltd BIFUNCTIONAL MOLECULES
AU5785999A (en) 1998-08-25 2000-03-14 University Of Washington Streptavidin mutants having secondary functional domains
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US7524628B2 (en) * 2000-07-25 2009-04-28 The Trustees Of The University Of Pennsylvania Method for detecting molecules expressing a selected epitope via fluorescent dyes
US6743592B1 (en) 2000-07-25 2004-06-01 The Trustees Of The University Of Pennsylvania Methods, systems and kits for immuno-detection of epitopes expressed on molecules
US7045286B2 (en) 2000-07-25 2006-05-16 The Trustees Of The University Of Pennsylvania Methods of detecting molecules expressing selected epitopes via fluorescent dyes
US6998234B2 (en) 2000-11-03 2006-02-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
WO2003045309A2 (en) * 2001-11-21 2003-06-05 The Trustees Of The University Of Pennsylvania Peptides, peptide compositions,and methods of use in binding p 185

Also Published As

Publication number Publication date
AU2005216126A1 (en) 2005-09-09
US20080206136A1 (en) 2008-08-28
AU2005216126B2 (en) 2011-04-07
EP1718323B1 (en) 2011-12-07
EP1718323A2 (en) 2006-11-08
ATE536367T1 (de) 2011-12-15
US7906624B2 (en) 2011-03-15
WO2005081898A3 (en) 2006-02-02
JP2007528725A (ja) 2007-10-18
CA2556832A1 (en) 2005-09-09
EP1718323A4 (en) 2008-12-31
WO2005081898A2 (en) 2005-09-09
EP2392586A1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
HK1100260A1 (en) Binding peptidomimetics and uses of the same
Wenzel et al. Conformational constraints in protein degradation by the 20S proteasome
NZ580378A (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
HK1092481A1 (en) Polypeptides having binding affinity for her2
MX357562B (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas vip3a de bacillus thuringiensis y metodos para su uso.
PH12013502425A1 (en) Smoothened polypeptides and methods of use
FI3778885T3 (fi) Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi
ATE550041T1 (de) Transglutaminase-vermittelte konjugation von peptiden
HK1091217A1 (en) Tuberculosis vaccine with improved efficacy
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2007018619A3 (en) Chimeric therapeutic agents
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
DE602005025141D1 (de) In Zellen eindringende Peptide als Träger für Moleküle
NZ334839A (en) Polynucleotide molecules encoding neospora proteins and uses thereof
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
TW200604207A (en) A superantigen fusion protein and the use thereof
WO2005058944A3 (en) Immunogenic peptides fragments of xage-1
EP1957660A4 (en) MATERIALS AND METHODS FOR ENHANCING THE EXPRESSION OF A PEPTIDE CHAIN
DE10394174D2 (de) Peptide mit hohem Cysteingehalt
EP1221485A3 (en) Polynucleotide molecules encoding neospora proteins
GB0520568D0 (en) Receptor
TH85387B (th) อินเทอร์เฟอรอน-อัลฟา โพลีเทปไทด์ และคอนจูเกต
GEP20084388B (en) High expression locus vector based on ferritin heavy chain gene locus
CO5400145A1 (es) Proteina asociada con enfermedad

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190221